Dallas, TX

RETINA FOUNDATION OF THE SOUTHWEST

EIN 51-0151514

Health & Wellness Medical Research & Training Children & youth Patients & families Seniors

Mission

To prevent vision loss and restore sight through innovative research and treatment for pediatric eye conditions, inherited retinal diseases, and age-related macular degeneration.

IRS-recognized 501(c)(3) public charity Contributions are tax-deductible

Claim this page Visit retinafoundation.org

About RETINA FOUNDATION OF THE SOUTHWEST

The Retina Foundation of the Southwest is an independent, Dallas-based vision research center founded in 1975 that focuses on preventing vision loss and restoring sight through translational laboratory research and patient-facing clinical trials. Its scientific teams work on gene therapy, gene editing, stem cell approaches, artificial intelligence and virtual-reality tools to diagnose, monitor and develop treatments for age-related macular degeneration (AMD), inherited retinal diseases (IRDs) and pediatric eye conditions.

The organization operates multiple laboratories and serves as a regional clinical-trial and patient-care hub that provides free vision assessments and genetic testing/counseling while partnering with academic centers, biotechnology companies and government funders. In recent years it has expanded clinical trial capacity, published and contributed to high-profile clinical research, and launched targeted programs to accelerate diagnostics and personalized therapies for patients and families affected by retinal disease.

Notable achievements

2024 Impact Report highlights

Published a 2024 Impact Report documenting growth in clinical trials, patient assessments, and translational projects; set multi-year goals to increase trials, hire additional MDs, expand facilities and accelerate research outcomes.

Launched sibling stem-cell AMD study (2024)

Opened a pioneering sibling study using ocular stem cells at the Henderson Ocular Stem Cell Laboratory to analyze genetic differences that explain varying AMD outcomes between siblings.

Enrollment in advanced gene-therapy trials (2024)

Enrolled the first patient at the center for Beacon Therapeutics’ VISTA Phase 2/3 AGTC-501 study and participated in multiple industry- and investigator‑sponsored Phase 1–3 trials, advancing options for X-linked retinitis pigmentosa, Stargardt disease and other IRDs.

At a glance

Total assets: $13.7M
Annual revenue: $8.4M
Tax status: 501(c)(3)Public charity
EIN: 51-0151514
Location: Dallas, TX
Website: retinafoundation.org
On Mahalo since: September 2026

Financial figures from the IRS Business Master File, the IRS’s registry of tax-exempt organizations.

Recognition

Charity Navigator: Four-Star rating and a high accountability/financial transparency score (reported score in public rating profile).

Contributed to high-profile peer-reviewed research: center investigators co-authored and led work from the BRILLANCE CRISPR clinical trial that was featured in a leading medical journal.

Regional philanthropic and community support demonstrated by major gifts and successful fundraising initiatives (including matching challenges and Visionary Luncheon proceeds that materially increased research funding in 2024).

Is this your organization?

Claim this page to keep it current — add your logo, publish campaigns, and reach the donors and advisors discovering you on Mahalo.

Claim this page